LEO Pharma A/S
http://www.leo-pharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From LEO Pharma A/S
Nordics BioPharma Sector In Rude Health Despite Global Downturn
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.
Propella Acquisition To Shore Up Astellas’s Prostate Cancer Presence
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Digital Health Roundup: HLTH, LSX, AdvaMed; FDA And Pre-Determined Change Control Plans
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with behavioral health experts on implementing AI solutions to help ease the administrative burden on clinicians as well as recent coverage from the LSX Congress USA and HLTH conferences. Reed Miller discusses findings of EY’s annual pulse of the medtech industry report and Hannah Daniel discusses FDA guidance on regulating AI/ML.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- LEO Pharma Inc.
- Peplin, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice